Roivant Sciences is combining with Montes Archimedes Acquisition Corp (MAAC), a particular purpose acquisition company sponsored by Patient Square Capital.
If you are not happy with the results below please do another search
50 search results for:
The U.S. Food and Drug Administration greenlit AstraZeneca’s Farxiga (dapagliflozin) under priority review for the treatment of chronic kidney disease in patients at risk of progression with or without type 2 diabetes.
Passage Bio Inc. and InformedDNA announced a collaboration to provide no-cost genetic counseling and testing for adults who have been diagnosed by their physicians with Frontotemporal Dementia (FTD).
More than 60 U.S. stadiums and other venues are deploying an app from Clear to verify people’s Covid-19 status, placing the New York company known for its airport security fast lanes at the forefront of a national debate over “vaccine passports.”
India’s daily Covid-19 shots fell sharply from an all-time high reached in early April as domestic companies struggle to boost supplies and imports are limited, even as the country fights the world’s worst surge in infections. Pfizer said on May 3 the company was in discussions with the Indian government seeking an “expedited approval pathway” for its vaccine.
U.S. President Joe Biden on May 3 imposed new travel restrictions on India in light of the Covid-19 epidemic, barring most non-U.S. citizens from entering the United States.
The Biden administration said on April 30 it is extending face mask requirements across all U.S. transportation networks through Sept. 13 to address the spread of Covid-19.
In a roundup review of scientific studies recently published, a study out of RCSI University of Medicine and Health Sciences and the HSE Health Protection Surveillance Centre (HPSC) in Ireland further defined the association between comorbidities and poor outcomes with Covid-19.
The United States had fully vaccinated 101,407,318 people for Covid-19 as of the morning of April 30, accounting for 30.5 percent of the population, the U.S. Centers for Disease Control and Prevention said.
An investigational Alzheimer’s disease (AD) drug from Tetra Therapeutics appeared to improve language ability and learning in adults with Fragile X Syndrome, according to a new study reported in Nature Medicine.